Pulnovo Medical Names Dr. Francis Duhay as Global Chief Medical Officer
PorAinvest
lunes, 25 de agosto de 2025, 4:38 am ET1 min de lectura
EW--
Prior to joining Pulnovo, Dr. Duhay served as the Chief Medical Officer at Edwards Lifesciences (NYSE: EW), where he played a crucial role in the development, clinical validation, and worldwide adoption of Transcatheter Aortic Valve Replacement (TAVR). The TAVR program, now recognized as one of the most successful cardiovascular procedures in history, generates over $4.0 billion in annual revenue and has been adopted in more than 80 countries [1].
Dr. Duhay's extensive experience includes leading 88 clinical studies across multiple specialties and collaborating with global regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS) [2]. His appointment at Pulnovo strengthens the company's global medical leadership as it advances its Pulmonary Artery Denervation (PADN) program and expands its footprint in international markets.
With Dr. Duhay's proven track record in bringing paradigm-shifting cardiovascular technologies from concept to global standard of care, Pulnovo is well-positioned for its next phase of innovation and growth.
References:
[1] https://www.prnewswire.com/news-releases/pulnovo-medical-names-dr-francis-duhay-as-global-chief-medical-officer-302537529.html
[2] https://www.stocktitan.net/news/EW/pulnovo-medical-names-dr-francis-duhay-as-global-chief-medical-jzn2kovl39s3.html
Pulnovo Medical has appointed Francis Duhay, MD, MBA, FACS, as its Global Chief Medical Officer. Duhay brings 25 years of experience in clinical medicine, medical device innovation, and executive leadership, including a role as Chief Medical Officer at Edwards Lifesciences. He will lead Pulnovo's Pulmonary Artery Denervation program and expand its international presence.
Pulnovo Medical, a global leader in mechanism-driven therapies for Pulmonary Hypertension (PH) and Heart Failure (HF), has appointed Dr. Francis Duhay, MD, MBA, FACS, as its Global Chief Medical Officer. Dr. Duhay brings over 25 years of experience in clinical medicine, medical device innovation, and executive leadership to the role.Prior to joining Pulnovo, Dr. Duhay served as the Chief Medical Officer at Edwards Lifesciences (NYSE: EW), where he played a crucial role in the development, clinical validation, and worldwide adoption of Transcatheter Aortic Valve Replacement (TAVR). The TAVR program, now recognized as one of the most successful cardiovascular procedures in history, generates over $4.0 billion in annual revenue and has been adopted in more than 80 countries [1].
Dr. Duhay's extensive experience includes leading 88 clinical studies across multiple specialties and collaborating with global regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS) [2]. His appointment at Pulnovo strengthens the company's global medical leadership as it advances its Pulmonary Artery Denervation (PADN) program and expands its footprint in international markets.
With Dr. Duhay's proven track record in bringing paradigm-shifting cardiovascular technologies from concept to global standard of care, Pulnovo is well-positioned for its next phase of innovation and growth.
References:
[1] https://www.prnewswire.com/news-releases/pulnovo-medical-names-dr-francis-duhay-as-global-chief-medical-officer-302537529.html
[2] https://www.stocktitan.net/news/EW/pulnovo-medical-names-dr-francis-duhay-as-global-chief-medical-jzn2kovl39s3.html

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema



Comentarios
Aún no hay comentarios